AR090795A1 - Metodo de tratamiento de las dermatosis sensibles a los esteroides, composicion farmaceutica - Google Patents
Metodo de tratamiento de las dermatosis sensibles a los esteroides, composicion farmaceuticaInfo
- Publication number
- AR090795A1 AR090795A1 ARP130101336A ARP130101336A AR090795A1 AR 090795 A1 AR090795 A1 AR 090795A1 AR P130101336 A ARP130101336 A AR P130101336A AR P130101336 A ARP130101336 A AR P130101336A AR 090795 A1 AR090795 A1 AR 090795A1
- Authority
- AR
- Argentina
- Prior art keywords
- chloro
- methyl
- dermatitis
- pyrazol
- ethyl
- Prior art date
Links
- 150000003431 steroids Chemical class 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 201000004624 Dermatitis Diseases 0.000 abstract 5
- 150000003839 salts Chemical class 0.000 abstract 4
- 241000124008 Mammalia Species 0.000 abstract 3
- 208000017520 skin disease Diseases 0.000 abstract 3
- AFJRDFWMXUECEW-LBPRGKRZSA-N N-[(2S)-1-amino-3-(3-fluorophenyl)propan-2-yl]-5-chloro-4-(4-chloro-2-methyl-3-pyrazolyl)-2-thiophenecarboxamide Chemical compound CN1N=CC(Cl)=C1C1=C(Cl)SC(C(=O)N[C@H](CN)CC=2C=C(F)C=CC=2)=C1 AFJRDFWMXUECEW-LBPRGKRZSA-N 0.000 abstract 2
- 201000009053 Neurodermatitis Diseases 0.000 abstract 2
- 208000003251 Pruritus Diseases 0.000 abstract 2
- 208000010668 atopic eczema Diseases 0.000 abstract 2
- 206010021198 ichthyosis Diseases 0.000 abstract 2
- AXTAPYRUEKNRBA-JTQLQIEISA-N n-[(2s)-1-amino-3-(3,4-difluorophenyl)propan-2-yl]-5-chloro-4-(4-chloro-2-methylpyrazol-3-yl)furan-2-carboxamide Chemical compound CN1N=CC(Cl)=C1C1=C(Cl)OC(C(=O)N[C@H](CN)CC=2C=C(F)C(F)=CC=2)=C1 AXTAPYRUEKNRBA-JTQLQIEISA-N 0.000 abstract 2
- 206010063409 Acarodermatitis Diseases 0.000 abstract 1
- 241000222122 Candida albicans Species 0.000 abstract 1
- 206010007134 Candida infections Diseases 0.000 abstract 1
- 206010012438 Dermatitis atopic Diseases 0.000 abstract 1
- 206010012442 Dermatitis contact Diseases 0.000 abstract 1
- 206010012504 Dermatophytosis Diseases 0.000 abstract 1
- 241001460074 Microsporum distortum Species 0.000 abstract 1
- 241001448624 Miliaria Species 0.000 abstract 1
- 206010034277 Pemphigoid Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 241000447727 Scabies Species 0.000 abstract 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 abstract 1
- 206010041955 Stasis dermatitis Diseases 0.000 abstract 1
- 208000002474 Tinea Diseases 0.000 abstract 1
- 206010048218 Xeroderma Diseases 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 201000008937 atopic dermatitis Diseases 0.000 abstract 1
- 208000000594 bullous pemphigoid Diseases 0.000 abstract 1
- 201000003984 candidiasis Diseases 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000010247 contact dermatitis Diseases 0.000 abstract 1
- 208000005005 intertrigo Diseases 0.000 abstract 1
- 201000011486 lichen planus Diseases 0.000 abstract 1
- 206010025135 lupus erythematosus Diseases 0.000 abstract 1
- 206010035114 pityriasis rosea Diseases 0.000 abstract 1
- 206010035116 pityriasis rubra pilaris Diseases 0.000 abstract 1
- 208000005687 scabies Diseases 0.000 abstract 1
- 208000008742 seborrheic dermatitis Diseases 0.000 abstract 1
- 238000011200 topical administration Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
Abstract
Un método para tratar las dermatosis sensibles a los esteroides en un mamífero, que lo necesite, que comprende la administración de una cantidad terapéuticamente eficaz de un compuesto seleccionado del grupo que consiste en: N-{(1S)-2-amino-1-[(3-fluorofenil)metil]etil}-5-cloro-4-(4-cloro-1-metil-1H-pirazol-5-il)-2-tiofenocarboxamida o una de sus sales farmacéuticamente aceptables; y N-{(1S)-2-amino-1-[(3,4-difluorofenil)metil]etil}-5-cloro-4-(4-cloro-1-metil-1H-pirazol-5-il)-2-furanocarboxamida o una de sus sales farmacéuticamente aceptables, a dicho mamífero. Reivindicación 7: El método de la reivindicación 1, en donde las dermatosis sensibles a los esteroides se seleccionan de: dermatitis de contacto, eczema, eczema infantil, dermatitis atópica, ictiosis, psoriasis, xeroderma, dermatitis seborreica, dermatitis numular, dermatitis herpetiforme, neurodermatitis, dermatitis por estasis, liquen simple crónico, dermatofitosis, candidiasis, intertrigo, sarna, pitiriasis rosada, liquen plano, pitiriasis rubra pilaris, penfigoide ampolloso, miliaria, eczema agudo y crónico, lupus eritematoso, reacciones fotoalérgicas, prurito, y combinaciones de las mismas. Reivindicación 16: Una composición farmacéutica para uso en el tratamiento de las dermatosis sensibles a los esteroides en mamíferos, que comprende N-{(1S)-2-amino-1-[(3-fluorofenil)metil]etil}-5-cloro-4-(4-cloro-1-metil-1H-pirazol-5-il)-2-tiofenocarboxamida o una de sus sales farmacéuticamente aceptables. Reivindicación 24: Una composición farmacéutica adecuada para administración tópica que comprende N-{(1S)-2-amino-1-[(3,4-difluorofenil)metil]etil}-5-cloro-4-(4-cloro-1-metil-1H-pirazol-5-il)-2-furanocarboxamida o una de sus sales farmacéuticamente aceptables.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261637390P | 2012-04-24 | 2012-04-24 | |
| US201361782565P | 2013-03-14 | 2013-03-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR090795A1 true AR090795A1 (es) | 2014-12-10 |
Family
ID=48143295
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130101336A AR090795A1 (es) | 2012-04-24 | 2013-04-22 | Metodo de tratamiento de las dermatosis sensibles a los esteroides, composicion farmaceutica |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US20150087683A1 (es) |
| EP (1) | EP2841053A1 (es) |
| JP (1) | JP2015514792A (es) |
| KR (1) | KR20150010943A (es) |
| CN (1) | CN104302275A (es) |
| AR (1) | AR090795A1 (es) |
| AU (1) | AU2013254849B2 (es) |
| BR (1) | BR112014026706A2 (es) |
| CA (1) | CA2873751A1 (es) |
| CL (1) | CL2014002861A1 (es) |
| CO (1) | CO7111283A2 (es) |
| CR (1) | CR20140491A (es) |
| DO (1) | DOP2014000238A (es) |
| EA (1) | EA201491914A1 (es) |
| HK (1) | HK1201726A1 (es) |
| IL (1) | IL235159A0 (es) |
| MX (1) | MX2014012904A (es) |
| NZ (1) | NZ628394A (es) |
| PE (1) | PE20142356A1 (es) |
| PH (1) | PH12014502400A1 (es) |
| SG (1) | SG11201406409VA (es) |
| TW (1) | TW201347758A (es) |
| UA (1) | UA113875C2 (es) |
| UY (1) | UY34762A (es) |
| WO (1) | WO2013160222A1 (es) |
| ZA (1) | ZA201407345B (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111821299A (zh) * | 2019-04-16 | 2020-10-27 | 天津合美医药科技有限公司 | 噻吩衍生物用于治疗免疫球蛋白E（IgE）介导的疾病的应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006002734A1 (en) * | 2004-07-01 | 2006-01-12 | Unilever N.V. | Moisture barrier |
| CA2578384A1 (en) * | 2004-09-06 | 2006-03-16 | Altana Pharma Ag | Novel pyrazolopyrimidines |
| US7705014B2 (en) * | 2005-04-12 | 2010-04-27 | Merck Sharp & Dohme Corp. | Inhibitors of AKT activity |
| UY30892A1 (es) * | 2007-02-07 | 2008-09-02 | Smithkline Beckman Corp | Inhibidores de la actividad akt |
| SG172926A1 (en) * | 2009-01-30 | 2011-08-29 | Glaxosmithkline Llc | Crystalline n-{(1-s)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride |
| CA2777085A1 (en) * | 2009-10-08 | 2011-04-14 | Glaxosmithkline Llc | Combination |
| WO2011146710A1 (en) * | 2010-05-21 | 2011-11-24 | Glaxosmithkline Llc | Combination |
-
2013
- 2013-04-22 US US14/394,394 patent/US20150087683A1/en not_active Abandoned
- 2013-04-22 JP JP2015507484A patent/JP2015514792A/ja active Pending
- 2013-04-22 SG SG11201406409VA patent/SG11201406409VA/en unknown
- 2013-04-22 BR BR112014026706A patent/BR112014026706A2/pt not_active IP Right Cessation
- 2013-04-22 PE PE2014001697A patent/PE20142356A1/es not_active Application Discontinuation
- 2013-04-22 EA EA201491914A patent/EA201491914A1/ru unknown
- 2013-04-22 TW TW102114114A patent/TW201347758A/zh unknown
- 2013-04-22 AR ARP130101336A patent/AR090795A1/es unknown
- 2013-04-22 NZ NZ628394A patent/NZ628394A/en not_active IP Right Cessation
- 2013-04-22 CN CN201380025996.5A patent/CN104302275A/zh active Pending
- 2013-04-22 UA UAA201412609A patent/UA113875C2/uk unknown
- 2013-04-22 KR KR20147029737A patent/KR20150010943A/ko not_active Application Discontinuation
- 2013-04-22 CA CA2873751A patent/CA2873751A1/en not_active Abandoned
- 2013-04-22 EP EP13717779.6A patent/EP2841053A1/en not_active Withdrawn
- 2013-04-22 MX MX2014012904A patent/MX2014012904A/es unknown
- 2013-04-22 WO PCT/EP2013/058249 patent/WO2013160222A1/en active Application Filing
- 2013-04-22 AU AU2013254849A patent/AU2013254849B2/en not_active Ceased
- 2013-04-23 UY UY0001034762A patent/UY34762A/es not_active Application Discontinuation
-
2014
- 2014-10-09 ZA ZA2014/07345A patent/ZA201407345B/en unknown
- 2014-10-19 IL IL235159A patent/IL235159A0/en unknown
- 2014-10-23 DO DO2014000238A patent/DOP2014000238A/es unknown
- 2014-10-23 CL CL2014002861A patent/CL2014002861A1/es unknown
- 2014-10-23 CO CO14235154A patent/CO7111283A2/es unknown
- 2014-10-24 CR CR20140491A patent/CR20140491A/es unknown
- 2014-10-24 PH PH12014502400A patent/PH12014502400A1/en unknown
-
2015
- 2015-03-05 HK HK15102257.7A patent/HK1201726A1/xx unknown
-
2016
- 2016-02-02 US US15/013,227 patent/US20160143885A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20150087683A1 (en) | 2015-03-26 |
| BR112014026706A2 (pt) | 2017-06-27 |
| HK1201726A1 (en) | 2015-09-11 |
| IL235159A0 (en) | 2014-12-31 |
| CA2873751A1 (en) | 2013-10-31 |
| KR20150010943A (ko) | 2015-01-29 |
| WO2013160222A1 (en) | 2013-10-31 |
| AU2013254849A1 (en) | 2014-11-06 |
| EA201491914A1 (ru) | 2015-01-30 |
| PE20142356A1 (es) | 2015-01-30 |
| EP2841053A1 (en) | 2015-03-04 |
| JP2015514792A (ja) | 2015-05-21 |
| MX2014012904A (es) | 2014-11-21 |
| NZ628394A (en) | 2016-02-26 |
| UA113875C2 (uk) | 2017-03-27 |
| CO7111283A2 (es) | 2014-11-10 |
| PH12014502400A1 (en) | 2015-01-12 |
| CN104302275A (zh) | 2015-01-21 |
| UY34762A (es) | 2013-11-29 |
| TW201347758A (zh) | 2013-12-01 |
| ZA201407345B (en) | 2015-11-25 |
| CR20140491A (es) | 2014-12-22 |
| AU2013254849B2 (en) | 2016-05-26 |
| CL2014002861A1 (es) | 2015-01-16 |
| DOP2014000238A (es) | 2014-12-15 |
| SG11201406409VA (en) | 2014-11-27 |
| US20160143885A1 (en) | 2016-05-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018006489A2 (pt) | composições e métodos para inibir a expressão gênica de lpa | |
| DOP2016000071A (es) | Inhibidores de tirosina cinasa de bruton | |
| BR112018003984A2 (pt) | anticorpos | |
| BR112016012615A8 (pt) | sistemas, e kit | |
| BR112016008576A2 (pt) | Formulações aquosas estáveis de anticorpos e forma farmacêutica de dosagem unitária | |
| MA38399A1 (fr) | Formulation sous forme de comprimé, utile pour traiter l'insuffisance cardiaque aiguë et l'insuffisance cardiaque chronique | |
| CL2019001447A1 (es) | Preparación de complejos sólidos de ciclodextrina para suministro de ingredientes farmacéuticos activos oftálmicos. | |
| BR112015023658A2 (pt) | formulação de vitamina d de liberação modificada, estabilizada e método de administração desta | |
| CU24486B1 (es) | Dispersión sólida amorfa que comprende taxano, tabletas comprendiendo la misma y método para prepararla | |
| CL2015000418A1 (es) | Formulacion acuosa topica que comprende un farmaco antiangiogenico que es un anticuerpo anti-vegf y un liposoma formado de un lipido a base de peg; su uso en el tratamiento de una enfermedad o condicion relacionada con vegf; y metodo para tratar cancer, psoriasis y edema macular diabetico, entre otras enfermedades. | |
| BR112017001860A2 (pt) | peptídeo sintético, composição farmacêutica, métodos, regime de dosagem, e, anticorpo monoclonal | |
| PH12015501554A1 (en) | Sustained-release lipid pre-concentrate of anionic pharmacologically active substances and pharmaceutical composition comprising the same | |
| AR086647A1 (es) | Metodos para tratar el mesotelioma con un compuesto inhibidor de la pi3k | |
| PH12017501750A1 (en) | 6-morpholinyl-2-pyrazolyl-9h-purine derivatives and their use as pi3k inhibitors | |
| AR090795A1 (es) | Metodo de tratamiento de las dermatosis sensibles a los esteroides, composicion farmaceutica | |
| FR3016694B1 (fr) | Procede d'assistance a la navigation pour giravion, par affichage dynamique d'une representation du monde exterieur construite en vol instantanement et/ou en differe | |
| MX2016010892A (es) | Agente para suprimir el progreso de o para mejorar la enfermedad renal cronica. | |
| BR112016023991A2 (pt) | ativadores de herg policíclicos | |
| PE20170902A1 (es) | Composicion dietetica con actividad antidislipidemica | |
| BR112015015483A8 (pt) | forma farmacêutica monolítica para a liberação modificada de uma combinação de ingredientes ativos e processo para produção da mesma | |
| Chou | DRESS: case report | |
| AR124515A2 (es) | 2-(1-(9h-purin-6-ilamino)propil)-3-(3-fluorofenil)-4h-cromen-4-ona y (s)-2-(1-(9h-purin-6-ilamino)propil)-3-(3-fluorofenil)-4h-cromen-4-ona, composición farmacéutica; métodos relacionados, y uso de dichos compuestos para fabricar medicamentos | |
| Kowalzick | Acute inflammation of seborrhoeic keratoses in an elderly patient: case report | |
| AR100153A1 (es) | Medicamento | |
| Ashoush | Mini-review: pharmacokinetics of omarigliptin, a once-weekly dipeptidyl peptidase-4 inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |